{"id":2538,"date":"2026-10-20T07:10:00","date_gmt":"2026-10-20T11:10:00","guid":{"rendered":"https:\/\/9biotx.com\/?p=2538"},"modified":"2026-10-20T07:12:00","modified_gmt":"2026-10-20T11:12:00","slug":"9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/","title":{"rendered":"9Bio Th\u00e9rapeutiques annonce une collaboration strat\u00e9gique visant \u00e0 faire progresser les anticorps conjugu\u00e9s \u00e0 des m\u00e9dicaments (ADC) de nouvelle g\u00e9n\u00e9ration pour le traitement des cancers m\u00e9tastatiques"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Qu\u00e9bec, QC, le 20 octobre 2026<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses cibl\u00e9es de nouvelle g\u00e9n\u00e9ration, annonce aujourd\u2019hui l\u2019approbation d\u2019une initiative de recherche collaborative avec le professeur Peter M. Siegel du Goodman Cancer Institute de l\u2019Universit\u00e9 McGill, Pierre Thibault de l\u2019Universit\u00e9 de Montr\u00e9al et Fr\u00e9d\u00e9ric Couture de TransBIOTech.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cette initiative fait partie des quatre collaborations entre les milieux industriel et universitaire soutenues par un investissement de 1,2 M$ annonc\u00e9 par M\u00e9dicament Qu\u00e9bec, rendu possible gr\u00e2ce au financement du gouvernement du Qu\u00e9bec. La collaboration permettra de mettre en place une plateforme int\u00e9gr\u00e9e de d\u00e9veloppement d\u2019anticorps conjugu\u00e9s \u00e0 des m\u00e9dicaments (ADC), r\u00e9unissant les expertises des milieux universitaire et industriel. 9Bio y contribuera activement gr\u00e2ce \u00e0 son expertise en d\u00e9veloppement d\u2019ADC et \u00e0 son programme 9B05, un nouvel ADC bisp\u00e9cifique ciblant les cancers m\u00e9tastatiques avanc\u00e9s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acc\u00e9l\u00e9rer le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses de nouvelle g\u00e9n\u00e9ration<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cette initiative vise \u00e0 relever les principaux d\u00e9fis li\u00e9s au d\u00e9veloppement des ADC en int\u00e9grant la mod\u00e9lisation computationnelle, l\u2019ing\u00e9nierie des anticorps, la caract\u00e9risation analytique, les essais biologiques et l\u2019\u00e9valuation translationnelle au sein d\u2019une plateforme coordonn\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En \u00e9valuant plus t\u00f4t dans le processus de d\u00e9veloppement les attributs critiques de qualit\u00e9 qui influencent l\u2019efficacit\u00e9, l\u2019innocuit\u00e9 et la fabricabilit\u00e9 des ADC, l\u2019initiative vise \u00e0 am\u00e9liorer la s\u00e9lection des candidats, \u00e0 r\u00e9duire les inefficacit\u00e9s du d\u00e9veloppement et \u00e0 acc\u00e9l\u00e9rer la progression des th\u00e9rapies prometteuses vers le d\u00e9veloppement clinique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour 9Bio, cette collaboration soutiendra directement la caract\u00e9risation et l\u2019optimisation de son programme 9B05 en combinant l\u2019expertise de l\u2019entreprise en d\u00e9veloppement th\u00e9rapeutique avec des comp\u00e9tences universitaires compl\u00e9mentaires et des infrastructures de recherche avanc\u00e9es.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au-del\u00e0 de l\u2019avancement du portefeuille de projets de 9Bio, cette initiative contribuera \u00e9galement \u00e0 renforcer les capacit\u00e9s de d\u00e9veloppement des ADC au Qu\u00e9bec en mettant en place des ressources et des expertises partag\u00e9es, accessibles aux chercheurs et aux entreprises de biotechnologie, favorisant ainsi l\u2019innovation au sein de l\u2019\u00e9cosyst\u00e8me biotechnologique qu\u00e9b\u00e9cois.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab Le d\u00e9veloppement d\u2019ADC bisp\u00e9cifiques efficaces n\u00e9cessite une compr\u00e9hension approfondie de la biologie tumorale, de l\u2019ing\u00e9nierie des anticorps et des propri\u00e9t\u00e9s mol\u00e9culaires qui influencent la performance th\u00e9rapeutique \u00bb, a d\u00e9clar\u00e9 Philipe Gobeil, Ph. D., pr\u00e9sident, chef de la direction scientifique et cofondateur de 9Bio Th\u00e9rapeutiques. \u00ab Cette collaboration nous permettra de mieux caract\u00e9riser et optimiser nos candidats, de g\u00e9n\u00e9rer des donn\u00e9es scientifiques essentielles et de prendre des d\u00e9cisions \u00e9clair\u00e9es tout au long du d\u00e9veloppement, dans le but de transformer nos recherches en nouvelles options th\u00e9rapeutiques susceptibles d\u2019apporter des b\u00e9n\u00e9fices concrets aux patients. \u00bb&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>R\u00e9pondre aux besoins m\u00e9dicaux urgents des patients atteints de cancers m\u00e9tastatiques<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Malgr\u00e9 les progr\u00e8s r\u00e9alis\u00e9s en oncologie, les patients atteints de cancers m\u00e9tastatiques avanc\u00e9s font toujours face \u00e0 d\u2019importants besoins m\u00e9dicaux non satisfaits. La r\u00e9sistance aux traitements, la progression de la maladie et le nombre limit\u00e9 d\u2019options th\u00e9rapeutiques offrant des r\u00e9ponses durables demeurent des d\u00e9fis majeurs, particuli\u00e8rement pour les patients atteints de cancers avanc\u00e9s du sein, colorectal, de l\u2019estomac et du foie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">9Bio cherche \u00e0 relever ces d\u00e9fis gr\u00e2ce \u00e0 son portefeuille de th\u00e9rapies cibl\u00e9es de nouvelle g\u00e9n\u00e9ration, notamment 9B05, un nouvel ADC bisp\u00e9cifique en d\u00e9veloppement pour les patients atteints de cancers m\u00e9tastatiques avanc\u00e9s, qui sera \u00e9galement \u00e9tudi\u00e9 dans le cadre de cette initiative.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">9B05 combine deux cibles tumorales compl\u00e9mentaires. La premi\u00e8re est un antig\u00e8ne valid\u00e9 cliniquement, associ\u00e9 aux propri\u00e9t\u00e9s des cellules souches canc\u00e9reuses, \u00e0 la r\u00e9sistance \u00e0 la chimioth\u00e9rapie et aux m\u00e9tastases, et pour lequel des donn\u00e9es cliniques ant\u00e9rieures de phase 1 ont d\u00e9montr\u00e9 une activit\u00e9 antitumorale. La seconde est un nouvel antig\u00e8ne tumoral associ\u00e9 \u00e0 la progression m\u00e9tastatique dans le foie \u00e0 partir de cancers primitifs colorectaux, gastriques et mammaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En combinant ces deux cibles au sein d\u2019un m\u00eame ADC bisp\u00e9cifique, 9Bio vise \u00e0 d\u00e9velopper une approche th\u00e9rapeutique diff\u00e9renci\u00e9e pour les cancers difficiles \u00e0 traiter. Le programme est actuellement \u00e0 l\u2019\u00e9tape de caract\u00e9risation et d\u2019optimisation des candidats principaux dans leur format bisp\u00e9cifique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab Les patients atteints de cancers m\u00e9tastatiques avanc\u00e9s ont un besoin urgent de meilleures options th\u00e9rapeutiques, particuli\u00e8rement lorsque leur maladie est devenue r\u00e9sistante aux traitements existants \u00bb, a d\u00e9clar\u00e9 Henrique de Carvalho, chef de la direction et cofondateur de 9Bio Th\u00e9rapeutiques. \u00ab Chez 9Bio, notre objectif est de transformer l\u2019innovation scientifique en avanc\u00e9es th\u00e9rapeutiques concr\u00e8tes pour ces patients. Gr\u00e2ce \u00e0 cette collaboration, nous investissons dans les expertises et les capacit\u00e9s n\u00e9cessaires pour acc\u00e9l\u00e9rer le d\u00e9veloppement de notre portefeuille de projets et rapprocher les nouveaux traitements prometteurs des essais cliniques. \u00bb<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-1 wp-block-paragraph\">Pour en savoir plus sur cette initiative, consultez <a href=\"https:\/\/medicamentquebec.ca\/index.php\/2026\/10\/19\/medicament-quebec-investit-12-m-dans-quatre-collaborations-entre-lindustrie-et-le-milieu-academique\/\" target=\"_blank\" rel=\"noreferrer noopener\">le communiqu\u00e9 de presse officiel de M\u00e9dicament Qu\u00e9bec<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">9Bio Th\u00e9rapeutiques est une entreprise de biotechnologie qui d\u00e9veloppe des th\u00e9rapies anticanc\u00e9reuses cibl\u00e9es de nouvelle g\u00e9n\u00e9ration afin de r\u00e9pondre \u00e0 d\u2019importants besoins m\u00e9dicaux non satisfaits en oncologie. Gr\u00e2ce \u00e0 sa plateforme exclusive d\u2019ing\u00e9nierie des prot\u00e9ines guid\u00e9e par l\u2019intelligence artificielle, Ninera\u2122, l\u2019entreprise con\u00e7oit et optimise des m\u00e9dicaments biologiques innovants, notamment des anticorps et des anticorps conjugu\u00e9s \u00e0 des m\u00e9dicaments (ADC), en mettant l\u2019accent sur l\u2019am\u00e9lioration de leur s\u00e9lectivit\u00e9 et de leur performance th\u00e9rapeutique. Son portefeuille comprend plusieurs programmes innovants d\u2019ADC ciblant des cancers avanc\u00e9s et difficiles \u00e0 traiter.<\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\">-30 \u2013<\/p>","protected":false},"excerpt":{"rendered":"<p>9Bio Therapeutics annonce une collaboration de recherche strat\u00e9gique avec des partenaires universitaires de premier plan, soutenue par M\u00e9dicament Qu\u00e9bec, afin de faire progresser son portefeuille d\u2019anticorps bisp\u00e9cifiques conjugu\u00e9s \u00e0 des m\u00e9dicaments (ADC) ciblant les cancers m\u00e9tastatiques avanc\u00e9s, pour lesquels d\u2019importants besoins m\u00e9dicaux demeurent non satisfaits, tout en contribuant au renforcement de l\u2019\u00e9cosyst\u00e8me biotechnologique qu\u00e9b\u00e9cois.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-2538","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"9Bio Therapeutics announces a strategic research collaboration with leading academic partners, supported by M\u00e9dicament Qu\u00e9bec, to advance its bispecific antibody-drug conjugate (ADC) pipeline targeting advanced metastatic cancers with significant unmet medical needs, while strengthening Qu\u00e9bec\u2019s biotechnology ecosystem.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-20T11:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-20T11:12:00+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers\",\"datePublished\":\"2026-10-20T11:10:00+00:00\",\"dateModified\":\"2026-10-20T11:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/\"},\"wordCount\":651,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/\",\"name\":\"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2026-10-20T11:10:00+00:00\",\"dateModified\":\"2026-10-20T11:12:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/","og_locale":"fr_CA","og_type":"article","og_title":"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics","og_description":"9Bio Therapeutics announces a strategic research collaboration with leading academic partners, supported by M\u00e9dicament Qu\u00e9bec, to advance its bispecific antibody-drug conjugate (ADC) pipeline targeting advanced metastatic cancers with significant unmet medical needs, while strengthening Qu\u00e9bec\u2019s biotechnology ecosystem.","og_url":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/","og_site_name":"9Bio Therapeutics","article_published_time":"2026-10-20T11:10:00+00:00","article_modified_time":"2026-10-20T11:12:00+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers","datePublished":"2026-10-20T11:10:00+00:00","dateModified":"2026-10-20T11:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/"},"wordCount":651,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/","url":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/","name":"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2026-10-20T11:10:00+00:00","dateModified":"2026-10-20T11:12:00+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-announces-strategic-collaboration-to-advance-next-generation-antibody-drug-conjugates-adcs-for-metastatic-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"9Bio Therapeutics Announces Strategic Collaboration to Advance Next-Generation Antibody-Drug Conjugates (ADCs) for Metastatic Cancers"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":0,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":9,"filter":"raw","cat_ID":1,"category_count":9,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=2538"}],"version-history":[{"count":3,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2538\/revisions"}],"predecessor-version":[{"id":2541,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2538\/revisions\/2541"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=2538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=2538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=2538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}